Corix Bioscience Stock

Corix Bioscience ROE

The Return on Equity (ROE) of Corix Bioscience (CXBS) as of Aug 7, 2026 is -98.97 %. In the previous year, Return on Equity (ROE) was -61.87 % — a change of 59.97% (lower).

ROE

-98.97 %

YoY

59.97%

Last updated:

In 2026, Corix Bioscience's return on equity (ROE) was -98.97 %, a 59.97% increase from the -61.87 % ROE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Corix Bioscience Stock analysis

What does Corix Bioscience do? Corix Bioscience is a company specialized in the production of cannabinoid-based products. It was founded in 2014 under the name American Housing Income Trust, a holding company focused on the American real estate market. In 2017, the company decided to restructure and change its name to Corix Bioscience. Since then, the company has become one of the leading manufacturers of CBD oils and other cannabinoid-based products. Corix Bioscience's business model is based on state-of-the-art technologies and innovation in the cannabinoid industry. The company collaborates with other firms to develop new products tailored to patient needs. The company aims to provide patients with a natural and safe alternative to conventional medical therapy. Corix Bioscience has five divisions. These include "Corix Bioscience," which focuses on the development of CBD-based products for the European market. "Corix Health" develops cannabinoid-based products specifically tailored to patient needs. "Subsidiaries" is responsible for collaborating with other companies to expand the product offering. "Licensing" offers licenses for technologies and rights to use innovative products. "Research and Development" focuses on advancing research and technologies in the cannabinoid industry. One of Corix Bioscience's most well-known products is CBD oil. It is extracted from specially bred hemp plants and is used for pain relief, anxiety, and other ailments. The company also offers CBD-based cosmetic products and food. Corix Bioscience is headquartered in Fresno, California, and is now internationally active. The company places special emphasis on the quality of its products and uses only natural and certified ingredients. Corix Bioscience advocates for fair and sustainable production and focuses on environmental protection and sustainability. The future prospects for Corix Bioscience are promising. The company operates in a forward-thinking market, focusing on innovation and sustainability. The developments in the market for cannabinoid-based products allow Corix Bioscience to expand its portfolio and offer more patients a natural alternative to conventional medical therapy. Corix Bioscience is one of the most popular companies on Eulerpool.

ROE Details

Decoding Corix Bioscience's Return on Equity (ROE)

Corix Bioscience's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Corix Bioscience's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Corix Bioscience's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Corix Bioscience’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Corix Bioscience stock

Return on Equity (ROE) of Corix Bioscience is -98.97 % in 2026.

Return on Equity (ROE) of Corix Bioscience changed from -61.87 % to -98.97 %, representing a 59.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Corix Bioscience since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Corix Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Corix Bioscience

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Corix Bioscience